An Exploration of Current and Future Considerations Impacting Awareness and Use of Open Clinical Trial Data

In this paper, we explore the challenges and opportunities sponsoring organizations and researchers face when sharing and utilizing clinical trial data for secondary analysis. With more data than ever before, there is increased emphasis on privacy and security.

Data transparency requires a balance between the desire to share data to drive additional insights and discoveries, and the need to protect the identity of the patients who participate in clinical trials.

Read the paper to hear experts’ perspectives from organizations on all sides of this critical movement, including Novartis, Duke Clinical Research Associates (DCRI) and SAS.